245 related articles for article (PubMed ID: 12544868)
21. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.
Vincenti F; Monaco A; Grinyo J; Kinkhabwala M; Roza A
Am J Transplant; 2003 Mar; 3(3):306-11. PubMed ID: 12614286
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.
Mehra MR; Zucker MJ; Wagoner L; Michler R; Boehmer J; Kovarik J; Vasquez A
J Heart Lung Transplant; 2005 Sep; 24(9):1297-304. PubMed ID: 16143248
[TBL] [Abstract][Full Text] [Related]
23. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH
Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358
[TBL] [Abstract][Full Text] [Related]
24. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
25. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
26. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation.
Lorber MI; Fastenau J; Wilson D; DiCesare J; Hall ML
Clin Transplant; 2000 Oct; 14(5):479-85. PubMed ID: 11048993
[TBL] [Abstract][Full Text] [Related]
27. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
28. Basiliximab induction in renal transplantation: long-term outcome.
Atlani M; Sharma RK; Gupta A
Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
[TBL] [Abstract][Full Text] [Related]
29. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
Aw MM; Taylor RM; Verma A; Parke A; Baker AJ; Hadzic D; Muiesan P; Rela M; Heaton ND; Mieli-Vergani G; Dhawan A
Transplantation; 2003 Mar; 75(6):796-9. PubMed ID: 12660504
[TBL] [Abstract][Full Text] [Related]
30. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
[TBL] [Abstract][Full Text] [Related]
31. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
Tan J; Yang S; Wu W
Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
[TBL] [Abstract][Full Text] [Related]
32. Economic analysis of basiliximab in renal transplantation.
Keown PA; Balshaw R; Krueger H; Baladi JF
Transplantation; 2001 Jun; 71(11):1573-9. PubMed ID: 11435967
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.
Offner G; Broyer M; Niaudet P; Loirat C; Mentser M; Lemire J; Crocker JF; Cochat P; Clark G; Chodoff L; Korn A; Hall M
Transplantation; 2002 Oct; 74(7):961-6. PubMed ID: 12394837
[TBL] [Abstract][Full Text] [Related]
34. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
[TBL] [Abstract][Full Text] [Related]
35. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
[TBL] [Abstract][Full Text] [Related]
36. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
[TBL] [Abstract][Full Text] [Related]
37. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
[TBL] [Abstract][Full Text] [Related]
38. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations.
Kim YS; Moon JI; Kim SI; Park K
Transplantation; 1999 Aug; 68(4):578-81. PubMed ID: 10480420
[TBL] [Abstract][Full Text] [Related]
39. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients.
Parrott NR; Hammad AQ; Watson CJ; Lodge JP; Andrews CD
Transplantation; 2005 Feb; 79(3):344-8. PubMed ID: 15699766
[TBL] [Abstract][Full Text] [Related]
40. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.
Duzova A; Buyan N; Bakkaloglu M; Dalgic A; Soylemezoglu O; Besbas N; Bakkaloglu A
Transplant Proc; 2003 Dec; 35(8):2878-80. PubMed ID: 14697926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
